Arcutis Biotherapeutics returns to profitability as Q2 2026 ZORYVE net product revenue reaches $129.9 million, raises 2026 net product sales guidance to $525–$540 million
https://finviz.com/stock?t=ARQT&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.